News | May 19, 2022
WHO validates Convidecia vaccine for Covid-19
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
This is the first major brand refresh of CanSinoBIO since its inception in 2009
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)